Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/113058
Title: | Safety of COVID-19 vaccination in patients with previous cerebral venous sinus thrombosis | Authors: | Gil Díaz, Aída Gil Hernández, Almudena Lozano Jiménez, Ana Isabel Benítez Peña, Jorge Conde-Martel, Alicia |
UNESCO Clasification: | 32 Ciencias médicas 3207 Patología 320718 Trombosis 3202 Epidemologia |
Keywords: | Cerebral Venous Sinus Thrombosis Covid-19 Vaccines |
Issue Date: | 2022 | Journal: | Thrombosis Research | Abstract: | Introduction: Cerebral venous sinus thrombosis (CVST) after coronavirus (COVID-19) vaccination has been reported. There are no data about thrombosis risk in prior CVST patients. The objective of the study was to describe short-term serious adverse events to COVID-19 vaccines in patients with history of CVST. Material and methods: We present an observational prospective study of patients with known CVST who received COVID-19 vaccination. Serious event rates within 30 days after second dose vaccination (except one dose for Janssen) were evaluated, including recurrences, hospital admission and death. Results: The 62 vaccinated patients received: BNT162b2 (Pfizer-BioNTech) in 43 patients (69.4%), mRNA-1273 (Moderna) in 7 patients (11.3%), AZD1222 (ChAdOx1) in 7 patients (11.3%) and Ad26.COV2.S (Janssen) in 5 patients (8.1%). There were no thrombotic recurrences within 30 days of vaccination (95% confidence interval, 0.0–5.8). There was one death (1.6%), not attributable to the vaccine. Conclusions: COVID-19 vaccines are safe for previous CVST patients. | URI: | http://hdl.handle.net/10553/113058 | ISSN: | 0049-3848 | DOI: | 10.1016/j.thromres.2021.12.004 | Source: | Thrombosis Research [ISSN 0049-3848], v. 209, p. 84-85, (Enero 2022) |
Appears in Collections: | Comentario |
SCOPUSTM
Citations
5
checked on Mar 30, 2025
WEB OF SCIENCETM
Citations
6
checked on Mar 30, 2025
Page view(s)
89
checked on Apr 20, 2024
Google ScholarTM
Check
Altmetric
Share
Export metadata
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.